| Attributes | Values |
|---|
| rdf:type
| |
| description
| - wetenschappelijk artikel (nl)
- наукова стаття, опублікована в лютому 1995 (uk)
- article scientifique publié en 1995 (fr)
- im Februar 1995 veröffentlichter wissenschaftlicher Artikel (de)
- artículu científicu espublizáu en febreru de 1995 (ast)
- artikull shkencor i botuar më 01 shkurt 1995 (sq)
- scientific article published on 01 February 1995 (en)
|
| publication date
| |
| publication date
| |
| language of work or name
| |
| language of work or name
| |
| author name string
| |
| author name string
| - Fujita T
- Tanaka T
- Ihara Y
- Ohnishi A
- Inoue T
- Yamamura Y
- Takagi N
- Orita Y
- Toyoki T
|
| rdfs:label
| - Aquaretic effect of a potent, orally active, nonpeptide V2 antagonist in men (en)
- Aquaretic effect of a potent, orally active, nonpeptide V2 antagonist in men (nl)
- Aquaretic effect of a potent, orally active, nonpeptide V2 antagonist in men (sq)
|
| skos:prefLabel
| - Aquaretic effect of a potent, orally active, nonpeptide V2 antagonist in men (en)
- Aquaretic effect of a potent, orally active, nonpeptide V2 antagonist in men (nl)
- Aquaretic effect of a potent, orally active, nonpeptide V2 antagonist in men (sq)
|
| name
| - Aquaretic effect of a potent, orally active, nonpeptide V2 antagonist in men (en)
- Aquaretic effect of a potent, orally active, nonpeptide V2 antagonist in men (nl)
- Aquaretic effect of a potent, orally active, nonpeptide V2 antagonist in men (sq)
|
| title
| |
| title
| - Aquaretic effect of a potent, orally active, nonpeptide V2 antagonist in men (en)
|
| page(s)
| |
| page(s)
| |
| instance of
| |
| instance of
| |
| PubMed ID
| |
| PubMed ID
| |
| PubMed ID
| |
| published in
| |
| published in
| |
| issue
| |
| volume
| |
| issue
| |
| volume
| |
| is about
of | |
| is cites work
of | - Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist
- Vasopressin contributes to hyperfiltration, albuminuria, and renal hypertrophy in diabetes mellitus: study in vasopressin-deficient Brattleboro rats
- Characterization of a novel nonpeptide vasopressin V(2)-agonist, OPC-51803, in cells transfected human vasopressin receptor subtypes
- Vaptans for the treatment of hyponatremia
- Molecular neurobiology and pharmacology of the vasopressin/oxytocin receptor family.
- Potential pharmacological interventions in polycystic kidney disease
- Hyponatremia and congestive heart failure: a marker of increased mortality and a target for therapy
- Pharmacology of vasopressin antagonists
- Polydipsia-hyponatraemia syndrome : epidemiology, clinical features and treatment
- Nephrogenic diabetes insipidus (NDI): clinical, laboratory and genetic characterization of five Brazilian patients.
- Clinical utility of tolvaptan in the management of hyponatremia in heart failure patients.
- Diagnosis, pathogenesis, and treatment prospects in cystic kidney disease
|
| is cites work
of | |
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)